Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 22, 2023 08:30 ET | Source: Panbela Therapeutics, Inc.

Panbela Announces Issuance of New Patent in Japan; Patent is for Claims of a Novel Process for the Production of SBP-101

MINNEAPOLIS, March 22, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
March 16, 2023 16:10 ET | Source: Panbela Therapeutics, Inc.

Panbela Provides Business Update and Reports Q4 and FY 2022 Financial Results

MINNEAPOLIS, March 16, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
March 08, 2023 08:00 ET | Source: Panbela Therapeutics, Inc.

Panbela to Host Fourth Quarter and Year End 2022 Earnings Conference Call on March 16, 2023

MINNEAPOLIS, March 08, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
March 07, 2023 08:00 ET | Source: Panbela Therapeutics, Inc.

Panbela Announces First Patient Enrolled in South Korea for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

MINNEAPOLIS, March 07, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
March 01, 2023 08:30 ET | Source: Panbela Therapeutics, Inc.

Acceptance of SBP-101 Abstract for Poster Presentation at American Association for Cancer Research (AACR)

MINNEAPOLIS, March 01, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
February 13, 2023 08:30 ET | Source: Panbela Therapeutics, Inc.

Panbela Announces Closing of Approximately $15 Million Public Offering, and Regains Compliance with Nasdaq Listing Standards

MINNEAPOLIS, Minn, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of...
January 26, 2023 08:41 ET | Source: Panbela Therapeutics, Inc.

Panbela Announces Pricing of Approximately $15 Million Public Offering

MINNEAPOLIS, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela” or the “Company”), a clinical stage company developing disruptive therapeutics for the treatment...
January 19, 2023 09:00 ET | Source: Panbela Therapeutics, Inc.

Panbela Announces Adoption of Commission Implementing Decision from the EMA for the Orphan Designation of Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

MINNEAPOLIS, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
January 12, 2023 11:00 ET | Source: Panbela Therapeutics, Inc.

Panbela Announces 1-for-40 Reverse Stock Split effective January 13, 2023

MINNEAPOLIS, Jan. 12, 2023 (GLOBE NEWSWIRE) -- -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent...
January 11, 2023 09:00 ET | Source: Panbela Therapeutics, Inc.

Panbela Starts Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, in Collaboration with Indiana University School of Medicine and JDRF

MINNEAPOLIS, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...